Table 2.
Summary of TB episodes, deaths during TB episodes and TB-specific admissions, 1 January 2019–30 September 2021.
| Characteristic | TB episodes | Died during TB episode | Died during TB-specific admission |
|---|---|---|---|
| (n = 107,179) | (n = 7,537) | (n = 1,673) | |
| n (%) | n (%) | n (%) | |
| Public health and social measures | |||
| Pre-COVID-19 | 54,961 (51) | 3,392 (45) | 753 (45) |
| Level 1 | 19,510 (18) | 1,500 (20) | 365 (22) |
| Level 2 | 7,470 (7.0) | 610 (8.1) | 140 (8.4) |
| Level 3 | 17,975 (17) | 1,427 (19) | 287 (17) |
| Level 4 | 4,332 (4.0) | 407 (5.4) | 87 (5.2) |
| Level 5 | 2,931 (2.7) | 201 (2.7) | 41 (2.5) |
| Age category, years | |||
| 18–29 | 28,680 (27) | 915 (12) | 258 (15) |
| 30–44 | 44,631 (42) | 2,794 (37) | 696 (42) |
| 45–59 | 25,449 (24) | 2,310 (31) | 473 (28) |
| ≥60 | 8,419 (7.9) | 1,518 (20) | 246 (15) |
| Previous episodes | |||
| 0 | 74,531 (70) | 4,855 (64) | 1,039 (62) |
| 1 | 22,357 (21) | 1,710 (23) | 423 (25) |
| 2 | 7,200 (6.7) | 646 (8.6) | 129 (7.7) |
| >3 | 3,091 (2.9) | 326 (4.3) | 82 (4.9) |
| Drug-resistant status | |||
| Drug-susceptible | 101,854 (95) | 6,965 (92) | 1,489 (89) |
| Drug-resistant | 5,325 (5.0) | 572 (7.6) | 184 (11) |
| HIV status during the episode | |||
| HIV-negative | 43,900 (41) | 2,267 (30) | 400 (24) |
| HIV-positive, not on ART | 4,441 (4.1) | 984 (13) | 284 (17) |
| HIV-positive, on ART | 42,281 (39) | 3,248 (43) | 809 (48) |
| HIV status unknown | 16,557 (15) | 1,038 (14) | 180 (11) |
| COVID-19 during episode | |||
| No infection | 104,449 (97) | 7,269 (96) | 1,655 (99) |
| Infection | 2,730 (2.5) | 268 (3.6) | 18 (1.1) |
| Diabetes | |||
| Negative | 100,161 (93) | 6,632 (88) | 1,533 (92) |
| Positive | 7,018 (6.5) | 905 (12) | 140 (8.4) |
ART = antiretroviral therapy.